Literature DB >> 16109717

Sox9 and p300 cooperatively regulate chromatin-mediated transcription.

Takayuki Furumatsu1, Masanao Tsuda, Kenji Yoshida, Noboru Taniguchi, Tatsuo Ito, Megumi Hashimoto, Takashi Ito, Hiroshi Asahara.   

Abstract

Chromatin structure is a fundamental component of gene regulation, expression, and cellular differentiation. We have previously reported that the multifunctional coactivator p300 is a member of the Sox9 (Sry-type high mobility group box 9)-related transcriptional apparatus and activates Sox9-dependent transcription during chondrogenesis. However, the mechanism of synergy between Sox9 and p300 in chromatin-mediated transcription has not been elucidated. In the present study we investigated the activity of Sox9 and p300 on chromatinized templates in vitro. Recombinant Sox9 was shown to be associated with several transcriptional cofactors including p300. In vitro transcription assays revealed that p300 potentiated Sox9-dependent transcription on chromatinized DNA and, importantly, was associated with hyperacetylated histones. Consistent with these results, the histone deacetylase inhibitor trichostatin A stimulated the expression of Sox9-regulated cartilage matrix genes and induced histone acetylation around the enhancer region of the collagen alpha1 (II) gene in chondrocytes. These findings suggest that Sox9 interacts with chromatin and activates transcription via regulation of chromatin modification.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16109717     DOI: 10.1074/jbc.M502409200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

Review 1.  Therapeutic molecular targets in human chondrosarcoma.

Authors:  Nuor Jamil; Sarah Howie; Donald M Salter
Journal:  Int J Exp Pathol       Date:  2010-10       Impact factor: 1.925

2.  Transforming Growth Factor-β-Induced KDM4B Promotes Chondrogenic Differentiation of Human Mesenchymal Stem Cells.

Authors:  Hye-Lim Lee; Bo Yu; Peng Deng; Cun-Yu Wang; Christine Hong
Journal:  Stem Cells       Date:  2015-11-17       Impact factor: 6.277

3.  microRNA-495 inhibits chondrogenic differentiation in human mesenchymal stem cells by targeting Sox9.

Authors:  Seulgi Lee; Dong Suk Yoon; Seungil Paik; Kyoung-Mi Lee; Yeonsue Jang; Jin Woo Lee
Journal:  Stem Cells Dev       Date:  2014-04-28       Impact factor: 3.272

4.  Cisplatin-Impaired Adipogenic Differentiation of Adipose Mesenchymal Stem Cells1.

Authors:  Yu-Hsun Chang; Hwan-Wun Liu; Tang-Yuan Chu; Yao-Tseng Wen; Rong-Kung Tsai; Dah-Ching Ding
Journal:  Cell Transplant       Date:  2017-02-03       Impact factor: 4.064

Review 5.  Transcriptional networks controlling chondrocyte proliferation and differentiation during endochondral ossification.

Authors:  Manuela Wuelling; Andrea Vortkamp
Journal:  Pediatr Nephrol       Date:  2009-12-01       Impact factor: 3.714

6.  Smad3 binds Scleraxis and Mohawk and regulates tendon matrix organization.

Authors:  Ellora Berthet; Carol Chen; Kristin Butcher; Richard A Schneider; Tamara Alliston; Mohana Amirtharajah
Journal:  J Orthop Res       Date:  2013-05-07       Impact factor: 3.494

Review 7.  Epigenetics as a New Frontier in Orthopedic Regenerative Medicine and Oncology.

Authors:  Andre J van Wijnen; Jennifer J Westendorf
Journal:  J Orthop Res       Date:  2019-04-25       Impact factor: 3.494

Review 8.  Significance of epigenetic landscape in cartilage regeneration from the cartilage development and pathology perspective.

Authors:  Jingting Li; James Ohliger; Ming Pei
Journal:  Stem Cells Dev       Date:  2014-04-01       Impact factor: 3.272

9.  Smad3 activates the Sox9-dependent transcription on chromatin.

Authors:  Takayuki Furumatsu; Toshifumi Ozaki; Hiroshi Asahara
Journal:  Int J Biochem Cell Biol       Date:  2008-11-08       Impact factor: 5.085

10.  Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid.

Authors:  Thierry Passeron; Julio C Valencia; Takeshi Namiki; Wilfred D Vieira; Hélène Passeron; Yoshinori Miyamura; Vincent J Hearing
Journal:  J Clin Invest       Date:  2009-03-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.